News


Generics substitution: Ireland’s plan for reference pricing

Published on 2012/11/26

A bill that will be debated this autumn seeks to introduce generics substitution and reference pricing for medicines and medical and surgical appliances in Ireland. Painful medicine for the health se...

0 views

ABPI concerned about medicines misconceptions

Published on 2012/11/23

The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies in the UK. In a new survey commissioned by the association issues of misu...

0 views

Italian Medicines Agency publishes concept paper on biosimilars

Published on 2012/11/21

The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) announced on 1 August 2012 the release of a concept paper on biosimilars. The purpose of the concept paper on biosimilar drugs is to...

0 views

Poor quality pharma ingredients abound in China

Published on 2012/11/19

Lack of regulatory enforcement in China is allowing poor quality pharmaceutical ingredients to be sold to drug manufacturers with potentially dangerous or even fatal consequences for patients. In Eur...

0 views

India’s patent laws coming under repeated challenges

Published on 2012/11/15

India’s patent laws are being challenged by Big Pharma. Novartis is challenging India for denying the pharma giant a patent for Glivec (imatinib mesylate), its blockbuster cancer drug. While Bayer i...

0 views

Maximising the potential of generics in Abu Dhabi

Published on 2012/11/13

IntroductionAll residents in Abu Dhabi have access to health care via mandatory health insurance. Nationals, who comprise 20% of the population with two-thirds under 30 years of age and half under 19 ...

0 views

Coupons help Big Pharma to fend off generics

Published on 2012/11/08

Pfizer’s success at using co-pay coupons to prevent patients switching from brand-name products to generics is encouraging other pharmaceutical giants to follow suit. When its patent for the choles...

4 views

Growing economies, growing markets: a bright future for biosimilars

Published on 2012/11/05

The biosimilars market, currently small and focused on a few disease areas and countries, is likely to grow considerably over the coming years, particularly in the US and emerging economies such as Br...

0 views

Biosimilar comparability debate continues

Published on 2012/11/01

Authors Schellekens and Moors comment on the response from EMA’s Biosimilar Medicinal Products Working Party to questions that they raised regarding EMA’s comprehensive biosimilar regulatory pathw...

2 views

Facts about generics for patients

Published on 2012/10/29

The costs of health care are rising across Europe through ageing populations resulting in more patients with chronic diseases, stricter clinical targets for managing patients with long term (chronic) ...

1 views

Positioning of biosimilars: commodity versus differentiated

Published on 2012/10/25

How to market a new biosimilar is a key question, especially when taking into consideration the costs that are associated with developing a biosimilar. Whether the biosimilar will be a bulk (commodity...

3 views

Generics reduce England’s drug spending

Published on 2012/10/22

According to a new report from the National Health Service in England, published on 31 July 2012, despite a 3.8% increase in the number of prescriptions dispensed in 2011 compared to 2010, spending o...

0 views